Analysts' average 12-month price target for Generate Biomedicines is $30.
Get informed when a big investor buys or sells
+ Follow$15.99
1 analysts in the last 4 months
High: $30 | Low: $30
No recommendations in the last 4 months.
The latest target price for GENB is $30. Investors often review this figure alongside Generate Biomedicines's historical trend and sector peers before judging valuation or financial health.
Generate Biomedicines trades near $15.99 while the consensus target sits at $30 (87.6% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.
After noting GENB's target price ($30), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.